Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

385 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies.
Vermeire S, van Assche G, Rutgeerts P. Vermeire S, et al. Among authors: van assche g. Aliment Pharmacol Ther. 2007 Jan 1;25(1):3-12. doi: 10.1111/j.1365-2036.2006.03134.x. Aliment Pharmacol Ther. 2007. PMID: 17229216 Review.
Concentration-dependent stimulation of cholinergic motor nerves or smooth muscle by [Nle13]motilin in the isolated rabbit gastric antrum.
Van Assche G, Depoortere I, Thijs T, Janssens JJ, Peeters TL. Van Assche G, et al. Eur J Pharmacol. 1997 Oct 22;337(2-3):267-74. doi: 10.1016/s0014-2999(97)01317-4. Eur J Pharmacol. 1997. PMID: 9430424
Dose-dependent effects of recombinant human interleukin-11 on contractile properties in rabbit 2,4,6-trinitrobenzene sulfonic acid colitis.
Depoortere I, Thijs T, van Assche G, Keith JC Jr, Peeters TL. Depoortere I, et al. Among authors: van assche g. J Pharmacol Exp Ther. 2000 Sep;294(3):983-90. J Pharmacol Exp Ther. 2000. PMID: 10945850
Anti-TNF agents in Crohn's disease.
Van Assche G, Rutgeerts P. Van Assche G, et al. Expert Opin Investig Drugs. 2000 Jan;9(1):103-11. doi: 10.1517/13543784.9.1.103. Expert Opin Investig Drugs. 2000. PMID: 11060664 Review.
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.
Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P. Cornillie F, et al. Among authors: van assche g. Aliment Pharmacol Ther. 2001 Apr;15(4):463-73. doi: 10.1046/j.1365-2036.2001.00956.x. Aliment Pharmacol Ther. 2001. PMID: 11284774 Clinical Trial.
Antiadhesion molecule therapy in inflammatory bowel disease.
van Assche G, Rutgeerts P. van Assche G, et al. Inflamm Bowel Dis. 2002 Jul;8(4):291-300. doi: 10.1097/00054725-200207000-00009. Inflamm Bowel Dis. 2002. PMID: 12131614 Review.
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.
Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P. Suenaert P, et al. Among authors: van assche g. Am J Gastroenterol. 2002 Aug;97(8):2000-4. doi: 10.1111/j.1572-0241.2002.05914.x. Am J Gastroenterol. 2002. PMID: 12190167
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Vermeire S, et al. Among authors: van assche g, van gossum a. Am J Gastroenterol. 2002 Sep;97(9):2357-63. doi: 10.1111/j.1572-0241.2002.05991.x. Am J Gastroenterol. 2002. PMID: 12358256
Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study.
Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R. Rutgeerts P, et al. Among authors: van assche g. Aliment Pharmacol Ther. 2003 Jan;17(2):185-92. doi: 10.1046/j.1365-2036.2003.01414.x. Aliment Pharmacol Ther. 2003. PMID: 12534402 Clinical Trial.
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Baert F, et al. Among authors: van assche g. N Engl J Med. 2003 Feb 13;348(7):601-8. doi: 10.1056/NEJMoa020888. N Engl J Med. 2003. PMID: 12584368 Clinical Trial.
385 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback